COMP <GO>
FLS vs TMO // ENTERPRISE SCALE & MARKET CAP
Flowserve Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: FLS 7
— TMO 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TMO
LAST: $80.35 (+11.89%) • MKT CAP: $10.19B
market-cap
$10.19B
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
market-cap
$262.22B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FLS VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FLS | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.70% | 9.30% | +1.40 | FLS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.9x | 30.4x | -11.50 | FLS | /valuation <GO> |
| Free Cash Flow Yield | 2.88% | 2.40% | +0.48 | FLS | /fcf-yield <GO> |
| Operating Margin | 8.50% | 17.40% | -8.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.30% | 15.10% | -7.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 3.80% | 3.90% | -0.10 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.08% | 0.24% | +0.84 | FLS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.66 | 4.50 | +0.16 | FLS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 62.9 | +3.40 | FLS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.94 | -0.03 | TMO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.3x | 36.3x | -9.00 | FLS | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $10.19B | $262.22B | -$252.03B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FLS REV | TMO REV | FLS GROSS % | TMO GROSS % | FLS FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.73B | $44.56B | 33.4% | — | $293.1M | $6.29B |
| FY 2024 | $4.56B | $42.88B | 31.5% | — | $220.2M | $7.27B |
| FY 2023 | $4.32B | $42.86B | — | — | $131.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FLS // BETA 0.91
TMO // BETA 0.94